Sage Therapeutics Inc (FRA:SG7)
€ 5.79 -0.394 (-6.37%) Market Cap: 328.82 Mil Enterprise Value: -195.46 Mil PE Ratio: 0 PB Ratio: 0.70 GF Score: 45/100

SAGE Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2022 / 12:30PM GMT
Release Date Price: €37.62 (+3.66%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

Good morning everybody and welcome to day 2 40th annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst, and it's my pleasure to introduce Sage Therapeutics and CEO, Barry Greene. Please note that following this presentation, we will move right into a Q&A session. We you can send in questions via the little blue ask a question button in your conference portal. And I'll do my best to work them into the conversation. So with that, Barry, thanks for joining us today, and let me turn things over to you for an update.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Yes. Thanks, Corey, and I want to thank the organizers for JPMorgan for having us here today. It's incredible that we're in another year of virtual, but I'm glad we're doing it. And we'll be making forward-looking statements. And as Corey said, I'm Barry Greene, CEO of Sage Therapeutics. And it's really my pleasure to provide an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot